Department of Biobank, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Cell Oncol (Dordr). 2024 Feb;47(1):175-188. doi: 10.1007/s13402-023-00861-2. Epub 2023 Aug 23.
Hepatocellular carcinoma (HCC) responds poorly to immunotherapy, and the durable response rate is 10-20%. Here, we aim to characterize HCC classifications based on lactate genes to identify patients who may benefit from immunotherapy.
Lactate-related genes were applied for HCC classification in the current study, and lactate Cluster 1 (LC1) and lactate Cluster 2 (LC2) were defined. Differential genes from LC1 and LC2 helped define the following lactate phenotype clusters: lactate phenotype Cluster 1 (LPC1), lactate phenotype Cluster 2 (LPC2) and lactate phenotype Cluster 3 (LPC3). Based on the cluster annotation, the lactate score was defined and analyzed to evaluate the immunotherapy response.
All the classified clusters were analyzed, and they showed different immune signatures. The survival rate of LPC3 was higher than that of LPC2 (LPC3 vs. LPC2, P = 0.027) and LPC1 (LPC3 vs. LPC1, P = 0.027). Then, the lactate score was annotated and confirmed to be effective in predicting responses to immune checkpoint blockade therapy.
In the current study, we developed a classification system for HCC and defined the lactate score, which was validated to be partially effective in estimating responses among tumor patients.
肝细胞癌（HCC）对免疫疗法反应不佳，持久缓解率为 10-20%。在这里，我们旨在根据乳酸基因对 HCC 进行分类，以确定可能受益于免疫疗法的患者。
本研究中应用了与乳酸相关的基因对 HCC 进行分类，并定义了乳酸簇 1（LC1）和乳酸簇 2（LC2）。LC1 和 LC2 的差异基因有助于定义以下乳酸表型簇：乳酸表型簇 1（LPC1）、乳酸表型簇 2（LPC2）和乳酸表型簇 3（LPC3）。基于簇注释，定义并分析了乳酸评分，以评估免疫治疗反应。
对所有分类的簇进行了分析，它们显示出不同的免疫特征。LPC3 的生存率高于 LPC2（LPC3 与 LPC2，P=0.027）和 LPC1（LPC3 与 LPC1，P=0.027）。然后，注释了乳酸评分并证实其可有效预测免疫检查点阻断治疗的反应。
在本研究中，我们开发了一种 HCC 分类系统，并定义了乳酸评分，该评分在评估肿瘤患者的反应方面被部分验证有效。
